Scarica l'app Stockscreener
209.16
0.81%
1.72
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$207.44
Aprire:
$207.48
Volume 24 ore:
107.42K
Relative Volume:
0.12
Capitalizzazione di mercato:
$23.15B
Reddito:
$11.28B
Utile/perdita netta:
$1.07B
Rapporto P/E:
23.07
EPS:
9.0657
Flusso di cassa netto:
$1.33B
1 W Prestazione:
-2.03%
1M Prestazione:
+2.98%
6M Prestazione:
+16.20%
1 anno Prestazione:
+24.41%
Intervallo 1D:
$207.48
$210.76
Intervallo di 1 settimana:
$206.34
$219.20
Portata 52W:
$164.65
$219.20
Quest Diagnostics Inc Stock (DGX) Company Profile
Nome
Quest Diagnostics Inc
Settore
Industria
Telefono
(973) 520-2700
Indirizzo
500 PLAZA DRIVE, SECAUCUS
Compare DGX vs TMO, DHR, IDXX, NTRA, A
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DGX
Quest Diagnostics Inc
|
209.10 | 22.96B | 11.28B | 1.07B | 1.33B | 9.0657 |
TMO
Thermo Fisher Scientific Inc
|
530.70 | 195.86B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
199.36 | 140.88B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.38 | 44.46B | 4.45B | 1.10B | 1.06B | 13.59 |
NTRA
Natera Inc
|
268.90 | 38.66B | 2.50B | -226.32M | 71.51M | -1.6412 |
A
Agilent Technologies Inc
|
133.16 | 37.93B | 7.23B | 1.41B | 1.09B | 4.979 |
Quest Diagnostics Inc Stock (DGX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-30 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-08-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2025-04-02 | Iniziato | Redburn Atlantic | Buy |
| 2025-03-04 | Downgrade | Citigroup | Buy → Neutral |
| 2025-01-06 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-12-17 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | Jefferies | Buy |
| 2024-10-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-08-28 | Ripresa | Evercore ISI | In-line |
| 2024-07-10 | Aggiornamento | Citigroup | Neutral → Buy |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2024-02-07 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-01-03 | Iniziato | Barclays | Equal Weight |
| 2023-12-12 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-06-29 | Iniziato | Piper Sandler | Neutral |
| 2023-05-02 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-04-03 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-01-23 | Iniziato | Evercore ISI | In-line |
| 2022-11-17 | Downgrade | Citigroup | Neutral → Sell |
| 2022-08-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-04-04 | Downgrade | Citigroup | Buy → Neutral |
| 2022-02-23 | Downgrade | UBS | Buy → Neutral |
| 2022-02-02 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-28 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-05-04 | Aggiornamento | UBS | Neutral → Buy |
| 2021-03-12 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-10-21 | Aggiornamento | Argus | Hold → Buy |
| 2020-07-29 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2020-07-14 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2020-06-09 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2020-06-02 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2020-04-28 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-04-27 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-04-27 | Aggiornamento | Wolfe Research | Underperform → Peer Perform |
| 2020-03-27 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-01-08 | Iniziato | Wells Fargo | Underweight |
| 2020-01-07 | Downgrade | Barclays | Overweight → Equal Weight |
| 2019-12-19 | Aggiornamento | BofA/Merrill | Underperform → Neutral |
| 2019-07-15 | Downgrade | Goldman | Neutral → Sell |
| 2019-04-02 | Aggiornamento | Jefferies | Hold → Buy |
| 2019-03-18 | Ripresa | Credit Suisse | Neutral |
| 2019-01-31 | Downgrade | Argus | Buy → Hold |
| 2019-01-17 | Iniziato | UBS | Neutral |
| 2019-01-03 | Downgrade | BofA/Merrill | Neutral → Underperform |
| 2018-12-03 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2018-11-30 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Quest Diagnostics Inc Borsa (DGX) Ultime notizie
Quest Diagnostics stock holds steady as diagnostics demand supports long-term growth - ad-hoc-news.de
Quest Diagnostics (NYSE:DGX) Offers a Secure and Sustainable Dividend with Strong Profitability - ChartMill
Quest Diagnostics (DGX) Proxy filing Summary - Quartr
Quest Diagnostics (DGX) Q4 2025 earnings summary - Quartr
Marijuana drives half of 2025 worker hair drug positives as fentanyl rates fall - Stock Titan
Quest Diagnostics stock stays supported by steady diagnostics demand - ad-hoc-news.de
Quest Diagnostics steadies its business model as demand for testing evolves - ad-hoc-news.de
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Quest Diagnostics updates digital tools as testing demand evolves - ad-hoc-news.de
Quest Diagnostics Incorporated Integrates Oncology Test Access with Flatiron Health Oncoemr for American Oncology Network - marketscreener.com
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI - marketscreener.com
Quest Diagnostics brings cancer test ordering into OncoEMR for 4,700 clinicians - Stock Titan
Quest Diagnostics (DGX) Q4 2024 earnings summary - Quartr
Quest Diagnostics Inc. stock outperforms competitors despite losses on the day - MarketWatch
Quest Diagnostics highlights its diagnostics role as investors assess the health services sector - ad-hoc-news.de
Quest Diagnostics stock steady as investors await the next catalyst - ad-hoc-news.de
Quest Diagnostics Quantiferon-TB Gold Pluslab test quietly underpins US tuberculosis screening - ad-hoc-news.de
Quest Diagnostics highlights long-term testing role in U.S. healthcare - ad-hoc-news.de
DGXQuest Diagnostics Inc Volatility & Greeks - Finviz
Quest Diagnostics Incorporated (DGX) hits fresh high: Is there still room to run? - MSN
If You Invested $1,000 in Quest Diagnostics Inc (DGX) - Stock Titan
Quest Diagnostics outlines its role in medical testing as investors weigh long-term demand - ad-hoc-news.de
Quest Diagnostics highlights its role in US healthcare. The stock reflects a stable diagnostics busi - ad-hoc-news.de
Director Timothy Wentworth receives 144 DGX phantom units as deferred pay - Stock Titan
Quest Diagnostics steadies after recent volatility as investors focus on core testing business - ad-hoc-news.de
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run? - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
Fund Update: 111,974 QUEST DIAGNOSTICS (DGX) shares added to EASTERN BANK portfolio - Quiver Quantitative
Quest Diagnostics's Q2 2026 Earnings: What to Expect - inkl
Quest Diagnostics (DGX) Q1 2025 earnings summary - Quartr
Quest Diagnostics Inc. stock outperforms competitors on strong trading day - MarketWatch
Quest Diagnostics earnings calendar in focus, shares trade steadily on the NYSE - ad-hoc-news.de
Price to earnings forward of Quest Diagnostics Incorporated – NYSE:DGX - TradingView
Quest Diagnostics highlights long-term strategy, shares hold near recent highs - ad-hoc-news.de
ETFs Investing in Quest Diagnostics Incorporated Stocks - TradingView
Quest Diagnostics Inc. stock underperforms Friday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics (DGX) Wins Nationwide Haystack MRD Access And Expands Into Psychiatry - Yahoo Finance
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Quest Diagnostics Incorporated Actuals & Estimates (NYSE:DGX) - TradingView
Days After Launch, Attunio Health Expands Precision Psychiatry Infrastructure with Quest Diagnostics and Getlabs - Morningstar
DGX Forecast — Price Target — Prediction for 2027 - TradingView
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Over - GuruFocus
Quest Diagnostics Receives New York Clearance for Haystack MRD Test - marketscreener.com
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing - PR Newswire
Quest Diagnostics updates 2025 guidance, shares trade near record valuation levels - Ad-hoc-news.de
New York clears Quest Diagnostics' cancer recurrence test statewide - Stock Titan
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now? - TradingView
Quest Diagnostics Prevails in Appeal Over 401(k) Fund Options - Bloomberg Law News
Quest Diagnostics StockWeekly outlook with earnings ahead - AD HOC NEWS
Is Quest Diagnostics Stock Underperforming the S&P 500? - inkl
Quest Diagnostics Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Quest Diagnostics Inc Azioni (DGX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.75%
1.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):